摘要
肺纤维化是以肺部纤维细胞异常增殖为表征,是一种慢性、进行性、致命性的纤维化肺间质疾病,其病发率现逐年增高,且治疗难度较大,因此寻找新的特效药物是提高肺纤维化疾病临床治愈率的关键。中药黄芪为补气上品,经过近年来的研究也证实黄芪是防治多脏器纤维化的主要中药之一。本文通过对中药黄芪主要活性成分黄芪总皂苷、黄芪甲苷、黄芪多糖、黄芪糖蛋白、黄芪黄酮等在治疗肺纤维化的药理作用及机制进行归纳总结,为后续中药黄芪及其活性成分在临床上的广泛应用提供理论依据。
Pulmonary fibrosis is a chronic progressive and fatal pulmonary interstitial fibrosis disease characterized by abnormal proliferation of pulmonary fibroblasts.With it s complicated etiological factors and treatment difficulty,looking for new specific drugs is the key to improve the curative rate of the disease.Astragalus membranaceus is the best traditional medicinal for invigorating Qi,recent studies have confirmed that it is one of the main Chinese medicinal for the prevention and treatment of multiple organ fibrosis.This study summarized the researches of pharmacological effect and mechanism of total saponins of Astragalus membranaceus(TSA),Astragaloside IV(AST),Astragalus polysaccharides(APS),Astragalus glycoprotein(AGP)and total flavonoides of Astragalus membranaceus(TFA)on pulmonary fibrosis,in order to provide theoretical foundation for future and clinical research of Astragalus membranaceus and its active ingredients.
作者
曹惠妍
何嘉郡
王盼盼
秦晨
贺廉清
陈丽娟
刘秀波
马伟
CAO Huiyan;HE Jiajun;WANG Panpan;QIN Chen;HE Lianqing;CHEN Lijuan;LIU Xiubo;MA Wei(School of Pharmacy,Heilongjiang University of Chinese Medicine,Harbin 150040,China;Jiamusi College,Heilongjiang University of Chinese Medicine,Jiamusi 154007,China)
出处
《中医药学报》
CAS
2023年第7期101-106,共6页
Acta Chinese Medicine and Pharmacology
基金
国家自然科学基金面上项目(821713927)
中央支持地方高校改革发展资金人才培养高水平项目(ZYRCB2021008)
黑龙江中医药大学中药健康相关产品研发及产业化专项(2019BJP06)。
关键词
黄芪
活性成分
肺纤维化
作用机制
Astragalus membranaceus
Active ingredients
Pulmonary fibrosis
Mechanism of action
作者简介
曹惠妍(1992-),女,硕士研究生,研究方向:中药资源与药用植物生物工程。;通讯作者:马伟(1969-),女,博士,研究员,博士生导师,研究方向:药用植物生物工程。
